Tags

Type your tag names separated by a space and hit enter

Evaluation of antimicrobial susceptibility for beta-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006).
Diagn Microbiol Infect Dis. 2008 Feb; 60(2):177-83.DM

Abstract

This antimicrobial resistance surveillance study was performed in 100 medical centers. Susceptibility testing (Etest; AB BIODISK, Solna, Sweden) of 9152 strains including Escherichia coli (991 strains), Klebsiella spp. (1000 strains), Enterobacter spp. (971 strains), Citrobacter spp. (803 strains), indole-positive Proteae spp. (834 strains), Serratia spp. (902 strains), Acinetobacter spp. (874 strains), Pseudomonas aeruginosa (992 strains), oxacillin-susceptible Staphylococcus aureus (984 strains), and coagulase-negative staphylococci (CoNS; 801 strains) was performed with 7 beta-lactams (cefepime, cefpirome, ceftazidime, cefoperazone/sulbactam, imipenem and piperacillin for Gram-negative bacteria, or oxacillin for Gram-positive bacteria). No strain resistance to these beta-lactams (except for ceftazidime) was found in oxacillin-susceptible S. aureus and CoNS. Of the E. coli clinical isolates, 17.1% were resistant to piperacillin, whereas 2.9% or less (cefpirome = 2.9%) were resistant to other beta-lactam agents. Klebsiella spp. strains were more susceptible to imipenem (99.9%), cefepime (99.2%), ceftazidime (98.6%), and cefpirome (98.3%). Isolates of Enterobacter spp., Citrobacter spp., indole-positive Proteae, and Serratia spp. were susceptible to imipenem, cefepime, and cefpirome as well. Acinetobacter spp. strains were least resistant to cefoperazone/sulbactam (0.7% resistance), imipenem (2.6%), cefepime (6.6%), and ceftazidime (7.7%) compared with other beta-lactam antibiotics tested. Isolates of P. aeruginosa were more susceptible to ceftazidime (8.7% resistance), cefoperazone/sulbactam (9.8%), and cefepime (8.9%) than piperacillin (11.9%), cefpirome (16.2%), and imipenem (12.4%). The percentage of imipenem-resistant P. aeruginosa was approximately 13% in clinical isolates in Japan. The proportion of strains resistant to beta-lactam antimicrobials has been decreasing compared with data from 2004, suggesting that reduced consumption of beta-lactams has reflected the decreased rates of resistant bacterial isolates in Japan.

Authors+Show Affiliations

Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Faculty of Medicine, Tokyo 1438540, Japan. yoishii@med.toho-u.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17931820

Citation

Ishii, Yoshikazu, et al. "Evaluation of Antimicrobial Susceptibility for Beta-lactams Using the Etest Method Against Clinical Isolates From 100 Medical Centers in Japan (2006)." Diagnostic Microbiology and Infectious Disease, vol. 60, no. 2, 2008, pp. 177-83.
Ishii Y, Tateda K, Yamaguchi K, et al. Evaluation of antimicrobial susceptibility for beta-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006). Diagn Microbiol Infect Dis. 2008;60(2):177-83.
Ishii, Y., Tateda, K., & Yamaguchi, K. (2008). Evaluation of antimicrobial susceptibility for beta-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006). Diagnostic Microbiology and Infectious Disease, 60(2), 177-83.
Ishii Y, et al. Evaluation of Antimicrobial Susceptibility for Beta-lactams Using the Etest Method Against Clinical Isolates From 100 Medical Centers in Japan (2006). Diagn Microbiol Infect Dis. 2008;60(2):177-83. PubMed PMID: 17931820.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of antimicrobial susceptibility for beta-lactams using the Etest method against clinical isolates from 100 medical centers in Japan (2006). AU - Ishii,Yoshikazu, AU - Tateda,Kazuhiro, AU - Yamaguchi,Keizo, AU - ,, Y1 - 2007/10/10/ PY - 2007/08/09/received PY - 2007/08/20/revised PY - 2007/08/20/accepted PY - 2007/10/13/pubmed PY - 2008/4/11/medline PY - 2007/10/13/entrez SP - 177 EP - 83 JF - Diagnostic microbiology and infectious disease JO - Diagn Microbiol Infect Dis VL - 60 IS - 2 N2 - This antimicrobial resistance surveillance study was performed in 100 medical centers. Susceptibility testing (Etest; AB BIODISK, Solna, Sweden) of 9152 strains including Escherichia coli (991 strains), Klebsiella spp. (1000 strains), Enterobacter spp. (971 strains), Citrobacter spp. (803 strains), indole-positive Proteae spp. (834 strains), Serratia spp. (902 strains), Acinetobacter spp. (874 strains), Pseudomonas aeruginosa (992 strains), oxacillin-susceptible Staphylococcus aureus (984 strains), and coagulase-negative staphylococci (CoNS; 801 strains) was performed with 7 beta-lactams (cefepime, cefpirome, ceftazidime, cefoperazone/sulbactam, imipenem and piperacillin for Gram-negative bacteria, or oxacillin for Gram-positive bacteria). No strain resistance to these beta-lactams (except for ceftazidime) was found in oxacillin-susceptible S. aureus and CoNS. Of the E. coli clinical isolates, 17.1% were resistant to piperacillin, whereas 2.9% or less (cefpirome = 2.9%) were resistant to other beta-lactam agents. Klebsiella spp. strains were more susceptible to imipenem (99.9%), cefepime (99.2%), ceftazidime (98.6%), and cefpirome (98.3%). Isolates of Enterobacter spp., Citrobacter spp., indole-positive Proteae, and Serratia spp. were susceptible to imipenem, cefepime, and cefpirome as well. Acinetobacter spp. strains were least resistant to cefoperazone/sulbactam (0.7% resistance), imipenem (2.6%), cefepime (6.6%), and ceftazidime (7.7%) compared with other beta-lactam antibiotics tested. Isolates of P. aeruginosa were more susceptible to ceftazidime (8.7% resistance), cefoperazone/sulbactam (9.8%), and cefepime (8.9%) than piperacillin (11.9%), cefpirome (16.2%), and imipenem (12.4%). The percentage of imipenem-resistant P. aeruginosa was approximately 13% in clinical isolates in Japan. The proportion of strains resistant to beta-lactam antimicrobials has been decreasing compared with data from 2004, suggesting that reduced consumption of beta-lactams has reflected the decreased rates of resistant bacterial isolates in Japan. SN - 0732-8893 UR - https://www.unboundmedicine.com/medline/citation/17931820/Evaluation_of_antimicrobial_susceptibility_for_beta_lactams_using_the_Etest_method_against_clinical_isolates_from_100_medical_centers_in_Japan__2006__ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0732-8893(07)00356-2 DB - PRIME DP - Unbound Medicine ER -